5.575USD-10.66%Mkt Cap: 5.30M USDP/E: —Last update: 2026-05-26
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap5.30M USD
Enterprise Value129.78M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.66M USD
Revenue/Share—
Last Price5.575 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.19
PEG—
EV/EBITDA-6.79
EV/Revenue—
P/S—
P/B3.58
EPS (TTM)-3.71
EPS (Forward)-0.60
52W Range
5.0503% of range20.99
52W High20.99 USD
52W Low5.050 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.82%
ROA-21.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.52M USD
CapEx (TTM)6.66K USD
FCF Margin—
FCF Yield-255.46%
Net Debt-17.81M USD
Net Debt/EBITDA0.93
Balance Sheet
Debt/Equity0.00
Current Ratio6.29
Quick Ratio5.37
Book Value/Sh1.710 USD
Cash/Share19.43 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:28
Split DateMay 15, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.950.30K
Float835.39K
Insiders9.22%
Institutions8.62%
Short Interest
Short Ratio6.3d
Short % Float3.90%
Short % Out.3.90%
Shares Short35.76K
Short (prev mo.)49.98K
Technical
SMA 508.252 (-32.4%)
SMA 2009.627 (-42.1%)
Beta1.40
S&P 52W Chg28.31%
Avg Vol (30d)8.58K
Avg Vol (10d)10.49K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—